You just read:

FDA Approves Supplemental New Drug Application (sNDA) for Boehringer Ingelheim's STIOLTO RESPIMAT for COPD Health-Related Quality of Life

News provided by

Boehringer Ingelheim Pharmaceuticals, Inc.

Mar 29, 2016, 08:00 ET